Agios Pharmaceuticals Inc logo

AGIO - Agios Pharmaceuticals Inc Share Price

$40.66 2.5  6.5%

Last Trade - 9:00pm

Sector
Healthcare
Size
Mid Cap
Market Cap £2.12bn
Enterprise Value £1.66bn
Revenue £95.6m
Position in Universe 1350th / 6316
Bullish
Bearish
Unlock AGIO Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AGIO Revenue Unlock AGIO Revenue

Net Income

AGIO Net Income Unlock AGIO Revenue

Normalised EPS

AGIO Normalised EPS Unlock AGIO Revenue

PE Ratio Range

AGIO PE Ratio Range Unlock AGIO Revenue

Dividend Yield Range

AGIO Dividend Yield Range Unlock AGIO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AGIO EPS Forecasts Unlock AGIO Revenue
Profile Summary

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.

Directors
Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated August 7, 2007
Public Since July 24, 2013
No. of Shareholders: 16
No. of Employees: 536
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 68,513,573
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AGIO Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AGIO
Upcoming Events for AGIO
Thursday 30th April, 2020 Estimate
Q1 2020 Agios Pharmaceuticals Inc Earnings Release
Thursday 28th May, 2020 Estimate
Agios Pharmaceuticals Inc Annual Shareholders Meeting
Thursday 30th July, 2020 Estimate
Q2 2020 Agios Pharmaceuticals Inc Earnings Release
Similar to AGIO
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.